|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Correlation with CAP/CTM HCV v2 was high in patient samples (mean titer difference: 0.05 log<sub>10</sub> with a 95% CI: 0.03-0.06 log<sub>10</sub>).
|
29518694 |
2018 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, although CAP/CTM and ART detected HCV RNA with comparable analytical sensitivity, CAP/CTM might be preferable for predicting the clinical outcomes of patients receiving protease inhibitor-based therapy.
|
28118381 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In patients infected with HCV genotype 3, sequential CAP/CTM HCV viral load results should be compared with caution and interpreted in the context of the specific assay version used.
|
27988503 |
2017 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mean difference between HPS/CTM and CAP/CTM at baseline (n=153) was 0.32 log<sub>10</sub> IU/mL HCV RNA.
|
28259054 |
2017 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, both Sansure HCV RNA and CAP/CTM HCV (Roche, Branchburg, NJ, USA) assays were used to detect HCV RNA in 346 EDTA anti-coagulated plasma samples from previous HCV-infected patients, during and after antiviral therapy.
|
26832356 |
2016 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HCV RNA levels were significantly higher with CAP/CTM than with ART (overall difference, +0.11 log10 IU/mL; P < .001).
|
26908802 |
2016 |
|
Hepatitis C
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study evaluated the performance characteristics of a second-generation real-time PCR assay, the Cobas AmpliPrep/Cobas TaqMan HCV quantitative test, version 2.0 (CAP/CTM HCV test, v2.0), designed with a novel dual-probe approach and an optimized automated extraction and amplification procedure.
|
23241371 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, CAP/CTM HCV v2.0 accurately quantifies HCV RNA in genotype 4 clinical specimens, regardless of the subtype, and can be confidently used in clinical trials and clinical practice with this genotype.
|
23325825 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also found that 16 (24.6%) by CAP/CTM and 28 (43.1%) by ART had a reappearance of residual HCV RNA during the telaprevir treatment period.
|
23684903 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
No correlation was observed between the sustained virological response (SVR) rate and the difference between the CAP/CTM HCV values and the ART HCV value before treatment.
|
22821355 |
2013 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, CAP/CTM v2 accurately quantifies HCV RNA across all HCV genotypes, including specimens with rare polymorphisms previously associated with underquantification.
|
21752967 |
2011 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
Results of CAP-CTM with truly undetectable HCV RNA and those <15IU/ml, which includes patients with residual viraemia (<15), were compared with the originally obtained results using the CA assay.
|
20385421 |
2010 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
A robust correlation was observed between the HCV core antigen and HCV RNA values by either of the HCV RNA quantitation assays applied to all genotypes with exception of genotype 4, for which R was higher with ART (R=0.95) than with CAP/CTM (R=0.80).
|
20872714 |
2010 |
|
Hepatitis C
|
0.100 |
Biomarker
|
disease |
BEFREE |
A new assay that employs automated specimen extraction and real-time RT-PCR (COBAS Ampliprep/COBAS TaqMan, "CAP/CTM", Roche Diagnostics, Pleasanton, USA) was designed for linear quantification and highly sensitive detection of HCV RNA.
|
18692434 |
2008 |
|
Hepatitis C
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Second, the CAP/CTM assay substantially underestimates HCV RNA levels in approximately 15% of genotype 2 samples and 30% of genotype 4 samples, probably because of mismatches with the target sequences due to the primer and/or probe design.
|
17525931 |
2007 |